|Bid||0.00 x 1200|
|Ask||0.00 x 4000|
|Day's Range||13.21 - 13.95|
|52 Week Range||9.51 - 29.35|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.86|
The big shareholder groups in Atreca, Inc. (NASDAQ:BCEL) have power over the company. Insiders often own a large chunk...
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will participate in the following upcoming virtual investor conferences: H.C. Wainwright & Co. 22nd Annual Global Investment Conference 2020 Wednesday, September 16, 2020 Presentation time: 3:30 p.m. EDTMorgan Stanley Virtual Global Healthcare Conference 2020 Thursday, September 17, 2020 Presentation time: 3:30 p.m. EDTA live audio webcast of each presentation can be accessed through the Events & Presentations section of the Company's website at ir.atreca.com. An archived replay of each webcast will be available on the Company's website for 90 days following the live presentations.About Atreca, Inc. Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.Contacts Atreca, Inc. Herb Cross Chief Financial Officer email@example.com Investors: Alex Gray, 650-779-9251 firstname.lastname@example.orgMedia: Sheryl Seapy, 213-262-9390 email@example.com Source: Atreca, Inc.
Atreca, Inc. (BCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).